The European Medicines Agency confirms the positive benefit / risk balance of orlistat-containing medicinal products. It recommends harmonizing the summary of product characteristics and patient leaflets of these medicinal products to ensure that information about adverse effects on the liver is the same for all them.
More information on the EMA website.